Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
The ECHELON-3 study showed BV + Len + R is an active and (relatively) tolerable in the rrDLBCL patient group. Interestingly, patients did not have to be CD30+ to see a benefit.